Segui
lorenzo  trippa
lorenzo trippa
Harvard and Dana Farber
Email verificata su jimmy.harvard.edu
Titolo
Citata da
Citata da
Anno
Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis
LM Spring, G Fell, A Arfe, C Sharma, R Greenup, KL Reynolds, BL Smith, ...
Clinical cancer research 26 (12), 2838-2848, 2020
5712020
Bifurcation analysis of single-cell gene expression data reveals epigenetic landscape
E Marco, RL Karp, G Guo, P Robson, AH Hart, L Trippa, GC Yuan
Proceedings of the National Academy of Sciences 111 (52), E5643-E5650, 2014
2782014
Prognostic role of circulating exosomal miRNAs in multiple myeloma.
SM others
Blood 129 (17), 2429--2436, 2017
266*2017
Adaptive platform trials: definition, design, conduct and reporting considerations
Nature Reviews Drug Discovery 18 (10), 797-807, 2019
2482019
On the restricted mean survival time curve in survival analysis
L Zhao, B Claggett, L Tian, H Uno, MA Pfeffer, SD Solomon, L Trippa, ...
Biometrics 72 (1), 215-221, 2016
2342016
Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples
M Riester, W Wei, L Waldron, AC Culhane, L Trippa, E Oliva, S Kim, ...
Journal of the National Cancer Institute 106 (5), dju048, 2014
2222014
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma
EK O'Donnell, JP Laubach, AJ Yee, T Chen, CA Huff, FG Basile, ...
British journal of haematology 182 (2), 222-230, 2018
1622018
Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression
M Bustoros, R Sklavenitis-Pistofidis, J Park, R Redd, B Zhitomirsky, ...
Journal of Clinical Oncology 38 (21), 2380, 2020
1462020
Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer
HA Parsons, J Rhoades, SC Reed, G Gydush, P Ram, P Exman, K Xiong, ...
Clinical Cancer Research 26 (11), 2556-2564, 2020
1342020
The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?
AM Vanderbeek, R Rahman, G Fell, S Ventz, T Chen, R Redd, ...
Neuro-oncology 20 (8), 1034-1043, 2018
1262018
Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab
OM Filho, G Viale, S Stein, L Trippa, DA Yardley, IA Mayer, VG Abramson, ...
Cancer discovery 11 (10), 2474-2487, 2021
1242021
Bayesian adaptive randomized trial design for patients with recurrent glioblastoma
L Trippa, EQ Lee, PY Wen, TT Batchelor, T Cloughesy, G Parmigiani, ...
Journal of Clinical Oncology 30 (26), 3258, 2012
1192012
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
TH Mouhieddine, AS Sperling, R Redd, J Park, M Leventhal, CJ Gibson, ...
Nature communications 11 (1), 2996, 2020
1182020
A comparison of Bayesian adaptive randomization and multi‐stage designs for multi‐arm clinical trials
JMS Wason, L Trippa
Statistics in medicine 33 (13), 2206-2221, 2014
1172014
Cross-study validation for the assessment of prediction algorithms
C Bernau, M Riester, AL Boulesteix, G Parmigiani, C Huttenhower, ...
Bioinformatics 30 (12), i105-i112, 2014
1122014
Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial
SM Tolaney, N Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, ...
Journal of Clinical Oncology 39 (21), 2375-2385, 2021
1112021
Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor–positive, ERBB2-negative metastatic breast cancer: A randomized …
SM Tolaney, R Barroso-Sousa, T Keenan, T Li, L Trippa, I Vaz-Luis, ...
JAMA oncology 6 (10), 1598-1605, 2020
1072020
Hazards of hazard ratios—deviations from model assumptions in immunotherapy
BM Alexander, JD Schoenfeld, L Trippa
New England Journal of Medicine 378 (12), 1158-1159, 2018
922018
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.
O Metzger Filho, G Viale, L Trippa, T Li, DA Yardley, IA Mayer, ...
Journal of Clinical Oncology 37 (15_suppl), 502-502, 2019
872019
Progression risk stratification of asymptomatic Waldenström macroglobulinemia
M Bustoros, R Sklavenitis-Pistofidis, P Kapoor, CJ Liu, E Kastritis, ...
Journal of Clinical Oncology 37 (16), 1403, 2019
842019
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20